The Journal of Allergy and Clinical Immunology
Volume 123, Issue 4 , Pages 763-769 , April 2009

Multiallergen immunotherapy for allergic rhinitis and asthma

  • Harold S. Nelson, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Harold S. Nelson, MD, National Jewish Health, 1400 Jackson St, Denver, CO 80206.

Received 24 September 2008 ,Revised 26 November 2008 ,Accepted 15 December 2008.

  • Image Result

    Comparison of the 3 sublingual immunotherapy treatments: effect on symptom and medication scores in 2003 and 2005. ns, Nonsignificant; B+G, birch plus grass. Reprinted with permission from Ann Allergy

    Comparison of the 3 sublingual immunotherapy treatments: effect on symptom and medication scores in 2003 and 2005. ns, Nonsignificant; B+G, birch plus grass. Reprinted with permission from Ann Allergy Asthma Immunol. 2007;98:274-80.

  • Image Result
    Study results: severity of asthma in the placebo and treated groups before study, after 4 years, and at the end of the study. The percentage of children for the treated and placebo groups in each time

    Study results: severity of asthma in the placebo and treated groups before study, after 4 years, and at the end of the study. The percentage of children for the treated and placebo groups in each time period equals 100%. Mild, Less than 11 days of wheezing per year; moderate, 11 to 70 days of wheezing per year; severe, more than 70 days of wheezing per year. Reproduced with permission from Pediatrics. 1968;42:799. ©1968 by the American Academy of Pediatrics.

 Editorial support was funded by Greer Laboratories, Inc.

 Disclosure of potential conflict of interest: H. S. Nelson is a principal investigator on research protocols for Schering-Plough, Boehringer-Ingelheim, TEVA, Novartis, Critical Therapeutics, AstraZeneca, Wyeth, Sepracor, Altana, and Genentech and has provided consultation to Genentech/Novartis, Curalogic, GlaxoSmithKline, Schering-Plough, Astellas, Ception, Boehringer-Ingelheim, AstraZeneca, Dey Laboratories, Dynavax Technologies, Abbott Laboratories, MediciNova, Johnson & Johnson, VentiRx, and Dyson.

PII: S0091-6749(08)02377-4

doi: 10.1016/j.jaci.2008.12.013

The Journal of Allergy and Clinical Immunology
Volume 123, Issue 4 , Pages 763-769 , April 2009

Article Tools

* Image Usage & Resolution